Prospective clinical trials can be stopped prematurely for safety breaches, demonstrated benefit to one group, or futility.

“yes they they do and they're they're generally kind of three reasons that studies are are stopped and again we're really talking about you know kind of prospective clinical trials here so um the first and most important of these is safety so remember we talked about phase one phase two phase three well phase one is all about safety phase two is about efficacy and safety phase three is really about Effectiveness and safety um but notice safety is in all of those so absolutely anytime there's a safety breach which means there is a statistically significant difference between an important safety metric in the between the groups that'll just stop the study the second thing that uh we'll stop a study is is benefit so again the predomed example of when it was first done is it stopped two-thirds of the way through because it was deemed that there was such a benefit to the group on the Mediterranean diet relative to the low-fat diet that it would have been unethical to let those people in the low-fat diet continue for another two and a half years on a diet that was uh so clearly increasing their risk of mortality and then the final thing that will stop a study prematurely is futility this is a little bit harder to understand but it actually comes down to that Hazard ratio concept which is able to measure risk temporally and and sort of in an aggregate fashion so if two-thirds of the way through a study there's no benefit and statistically you know that nothing that's going to happen in the remainder of the study is going to change that you stop the study it's futile to continue the study so so so those are basically your big three reasons why a study is going to be stopped”